ARTICLE | Clinical News

Unum reports Phase I data for ACTR087 in NHL

January 19, 2018 4:57 AM UTC

In November, Unum Therapeutics Inc. (Cambridge, Mass.) reported data from six evaluable patients with relapsed or refractory CD20-positive B cell non-Hodgkin's lymphoma (NHL) in the first dose cohort of the Phase I ATTCK-20-2 trial showing that ACTR087 (ATTCK20) plus Rituxan rituximab led to two complete responses and one partial response. No treatment-related serious adverse events, cytokine release syndrome (CRS) or neurotoxicity were reported. Data were also presented at the American Society of Hematology meeting in Atlanta in December.

The open-label, dose-escalation, U.S. trial evaluated dose limiting-toxicities (DLTs), maximum tolerated dose (MTD) and safety as its primary endpoints. Secondary endpoints include overall response rate (ORR), duration or response, progression free survival (PFS) and overall survival (OS)...